Adverum Biotechnologies Inc (ADVM) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.22x
Adverum Biotechnologies Inc (ADVM) has a Cash Flow-to-Debt Ratio of -0.22x as of September 2025, meaning its operating cash flow of $-28.11 Million could theoretically repay 0% of its total liabilities ($128.05 Million) in one year. See ADVM financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.22x
Operating CF / Total Liabilities
Operating Cash Flow
$-28.11 Million
USD
Total Liabilities
$128.05 Million
USD
Data as of
Sep 2025
Most recent filing
Adverum Biotechnologies Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Adverum Biotechnologies Inc across 13 annual periods. For the full cash flow conversion analysis, see ADVM cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Adverum Biotechnologies Inc (2012–2024)
Year-by-year debt coverage analysis for Adverum Biotechnologies Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.85x | $-92.46 Million | $109.13 Million | ▲ +17.5% |
| 2023 | -1.03x | $-90.90 Million | $88.55 Million | ▼ -20.5% |
| 2022 | -0.85x | $-108.09 Million | $126.85 Million | ▲ +2.4% |
| 2021 | -0.87x | $-107.83 Million | $123.54 Million | ▲ +46.9% |
| 2020 | -1.64x | $-79.29 Million | $48.22 Million | ▼ -59.8% |
| 2019 | -1.03x | $-49.17 Million | $47.77 Million | ▲ +76.5% |
| 2018 | -4.38x | $-53.96 Million | $12.33 Million | ▼ -72.3% |
| 2017 | -2.54x | $-45.42 Million | $17.88 Million | ▼ -25.7% |
| 2016 | -2.02x | $-38.37 Million | $18.98 Million | ▲ +32.9% |
| 2015 | -3.01x | $-35.34 Million | $11.73 Million | ▼ -562.8% |
| 2014 | -0.45x | $-5.65 Million | $12.42 Million | ▲ +72.8% |
| 2013 | -1.67x | $-2.17 Million | $1.30 Million | ▼ -82.2% |
| 2012 | -0.92x | $-1.27 Million | $1.38 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.